Abstract: The invention relates to Dengue chimeric viruses which are less prone to accumulate point mutations and genetic variations. In these Dengue chimeric viruses, the NS5 gene, which encodes polymerase, has been replaced by the corresponding NS5 sequence of a Yellow Fever virus.

Abstract: The invention relates to Dengue chimeric viruses which are less prone to accumulate point mutations and genetic variations. In these Dengue chimeric viruses, the NS5 gene, which encodes polymerase, has been replaced by the corresponding NS5 sequence of a Yellow Fever virus.

Abstract: The invention relates to Dengue chimeric viruses which are less prone to accumulate point mutations and genetic variations. In these Dengue chimeric viruses, the NS5 gene, which encodes polymerase, has been replaced by the corresponding NS5 sequence of a Yellow Fever virus.

Abstract: The invention relates to Dengue chimeric viruses which are less prone to accumulate point mutations and genetic variations. In these Dengue chimeric viruses, the NS5 gene, which encodes polymerase, has been replaced by the corresponding NS5 sequence of a Yellow Fever virus.

Abstract: The invention relates to live attenuated dengue serotype 3 virus strains which have been produced by site directed mutagenesis of an attenuated dengue 3 strain.

Abstract: The invention relates to a pharmaceutical composition intended for inducing in a host mammal a protective immune response against an antigen, at a mucosal effector site, which comprises at least two identical or different products each containing an inducing agent for the immune response, selected from the antigen and, provided the antigen is protein in nature, an expression cassette capable of expressing the antigen, for a concomitant or consecutive administration; one of the products being formulated so as to be administered via the nasobuccal route so that the inducing agent is targeted to the inducer site(s) for an immune response in the naso-oropharynx or the salivary glands, the other product being formulated so as to be administered via a suitable mucosal route other than the nasal route, so that the inducing agent is targeted to the inducer site(s) for an immune response at the effector site at which the immune response is sought.

Abstract: The present invention relates to the lower molecular weight subunit of the human transferrin receptor of a strain of N. meningitidis, in purified form, as well as to a vaccinal pharmaceutical composition intended for the prevention or attenuation of the effects of an N. meningitidis infection, containing the said subunit in purified form.

Abstract: A vaccinal pharmaceutical composition which comprises, as therapeutic agents, at least a first and a second molecule capable of binding to human transferrin; the said first molecule originating from a first strain of N. meningitidis which possesses a human transferrin receptor in which the lower molecular weight subunit (Tbp2) is recognised by an antiserum to the receptor of N. meningitidis strain 2394 (receptor 2394) and is not recognised by an antiserum to the receptor of N. meningitidis strain 2169 (receptor 2169); and at least a second molecule originating from a second strain of N. meningitidis which possesses a human transferrin receptor in which the lower molecular weight subunit (Tbp2) is recognised by an anti-receptor 2169 antiserum and is not recognised by an anti-receptor 2394 antiserum.

Abstract: A chromatography material comprises a solid support on which is fixed, as a ligan, desialyled gycolprotein selected from desialyled fetuin and desialyled haptoglobin. This material is used to purify protein antigens of bacteria of the Bordetella genus.